Chemotherapy for patients with advanced prostate carcinoma: A new option for therapy

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 3015-3021

  Oh, William K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Hormone refractory; Palliation; Prostate carcinoma

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CARBOPLATIN; CORTICOSTEROID; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; GONADORELIN; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID; SURAMIN; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDUCED DISEASE; DRUG STRUCTURE; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CARCINOMA; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0034660274     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<3015::aid-cncr18>3.0.co;2-m     Document Type: Conference Paper

References (33)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17:2506-13.
3. Isaacs JT. The biology of hormone-refractory prostate cancer: why does it develop? Urol Clin North Am 1999;26:263-73.
4. Dawson NA, McLeod DG. The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 1997;33:560-7.
5. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998;160:1220-9.
6. Scher HI, Mazumdar M, Kelly WK. Clinical trials in relapsed prostate cancer: defining the target. J Natl Cancer Inst 1996; 88:1623-30.
7. Figg, WD, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson N, et al. Lack of correlation between prostatespecific antigen and presence of measurable soft tissue mé tastases in hormone-refractory prostate cancer. Cancer Invest 1996;14:513-6.
8. Sabbatini P, Larson SM, Kremer A, Zhang ZF, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999;17:948-57.
9. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985;3:1013-21.
10. Kelly WK, Scher HI, Mazumda M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993;11:607-12.
11. Bubley G, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 1999;17:3461-7.
12. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-1764.
13. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997;15:382-9.
14. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999;59:2511-5.
15. Wilding GW. Endocrine control of prostate cancer. Cancer Surv 1995;23:43-52.
16. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, et al. High dose bicalutamide for androgen-independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159:149-55.
17. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257-60.
18. Kameda H, Small EJ, Reese DM, Correy M, Frohlich MA, et al. A Phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer [abstract]. Proc Am Soc Clin Oncol 1999;18:320a.
19. Chang WY, Prins GS. Estrogen receptor-beta: implications for the prostate gland. Prostate 1999;40:115-24.
20. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985;3:827-41.
21. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
22. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997;15:13-19.
23. Benson RC, Hartley-Asp B. Mechanisms of action and clinical uses of estramustine. Cancer Invest 1990;8:375-80.
24. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999;17:3160-6.
25. Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate carcinoma. J Clin Oncol 1997;15:3156-63.
26. Kelly K, Gaudin P, Slovin S, et al. Paclitaxel (T), estramustine (E) and carboplatin (C) in patients with advanced prostate cancer (PC) [abstract]. AUA Annual Meeting, 1998.
27. Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17:958-67.
28. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10:33-8.
29. Savarese DM, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N, et al. A phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Sem Oncol 1999;26(5 Suppl 17): 39-44.
30. Picus JL, Schultz M. A Phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC): long-term results [abstract]. Proc Am Soc Clin Oncol 1999;18:1206.
31. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997;277:1445-51.
32. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
33. Small EJ, Marshall ME, Reyno L, Natale R, Meyer M, Lenehan P, et al. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: results of a multi-center, double blind, phase III study in hormone refractory prostate cancer patients [abstract]. Proc Am Soc Clin Oncol 1998;17:308a.